Doximity, Inc. (NYSE:DOCS) Sees Analyst Optimism and Strong Growth Prospects

• click to rate

  Posted by John Deo Feb 6 - Filed in General - #financialmodelingprep  - 19 views
  
  • Analysts have raised the consensus price target for Doximity, Inc. (NYSEOCS) from $44.94 to $54, reflecting optimism about the company's performance.
  • Evercore ISI upgraded Doximity to a buy rating, highlighting stronger engagement metrics and deeper client relationships.
  • Doximity's stock has surged 101% year-to-date, driven by a 20% year-over-year revenue growth in Q2 2025 and the adoption of new AI-powered features.

  Doximity, Inc. (NYSEOCS) operates a cloud-based digital platform designed for medical professionals in the U.S. The platform offers tools for collaboration, patient care coordination, virtual visits, and career management. It primarily serves pharmaceutical manufacturers and healthcare systems, making it a key player in the digital healthcare sector.

  Analysts have shown increasing optimism about Doximity's stock over the past year. The consensus price target rose from $44.94 last year to $54 last month. However, there was a slight decrease from the last quarter's $56.14 to the current $54, indicating a minor adjustment in expectations. This reflects analysts' evolving views on the company's performance and market conditions.

  Evercore ISI recently upgraded Doximity to a buy rating, led by analyst Elizabeth Anderson, due to stronger engagement metrics and deeper client relationships. Despite a recent pullback in share price, Doximity reported a 20% year-over-year revenue growth in Q2 2025, surpassing management's guidance. This growth was driven by increased user adoption and higher revenue per user.

  Doximity's stock has surged 101% year-to-date, with a 34% jump following its latest earnings report. Stephens initiated coverage with an Equal Weight rating and a $55 price target, noting the company's growth profile in low-to-mid-teens percentages. The self-serve marketplace and new products are expected to drive revenue growth, though Stephens remains cautious about modeling above-consensus growth.

  Mizuho initiated coverage with a Neutral rating and a $55 price target, acknowledging volatility in quarterly top-line growth due to pharmaceutical digital ad spending. Despite challenges, Mizuho is confident in Doximity's potential for low double-digit annual revenue growth. The widespread adoption of Doximity's platform by over 80% of U.S. doctors solidifies its competitive position, supported by strong financial performance and new AI-powered features.